Early-stage biotech exits stealth mode with $5.3M funding boost

04/5/2013 | MedCityNews.com

Calif.-based Nurix has emerged from its stealth period with $5.3 million in equity funding from four investors, according to a securities filing. The biotech startup seeks to develop T-cell-specific immunosuppressant drugs for autoimmune diseases.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL